Based on 4 Wall Street analysts offering 12 month price targets for Gland Pharma Ltd. in the last 3 months. The average price target is ₹1,642.50 with a high forecast of ₹1,790.00 and a low forecast of ₹1,525.00. The average price target represents a -2.17% change from the last price of ₹1,678.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1524":"₹1,524","2101":"₹2,101","1668.25":"₹1,668.3","1812.5":"₹1,812.5","1956.75":"₹1,956.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1790,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.79K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1642.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.64K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1525,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.52K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1524,1668.25,1812.5,1956.75,2101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Nov<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1809.8,1808.2769230769231,1806.753846153846,1805.2307692307693,1803.7076923076922,1802.1846153846154,1800.6615384615384,1799.1384615384616,1797.6153846153845,1796.0923076923077,1794.5692307692307,1793.0461538461539,1791.5230769230768,{"y":1790,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1809.8,1796.930769230769,1784.0615384615385,1771.1923076923076,1758.323076923077,1745.4538461538461,1732.5846153846153,1719.7153846153847,1706.8461538461538,1693.976923076923,1681.1076923076923,1668.2384615384615,1655.3692307692309,{"y":1642.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1809.8,1787.8923076923077,1765.9846153846154,1744.076923076923,1722.1692307692308,1700.2615384615385,1678.353846153846,1656.4461538461537,1634.5384615384614,1612.6307692307691,1590.7230769230769,1568.8153846153846,1546.9076923076923,{"y":1525,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1963.61,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1768.17,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1796.88,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1693.98,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1820.38,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1801.23,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2100.49,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1833.25,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1799.9,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1650.85,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1779.4,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1779.4,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1809.8,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹1,790

Average Price Target₹1,643

Lowest Price Target₹1,525

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

Nomura

xxxxxxxxxxxxx

Upgraded

01/20/25

Downgraded

01/10/25

Reiterated

01/10/25

Reiterated

12/27/24

xxxxxxxxxxxxx

Best Analysts Covering Gland Pharma Ltd.

Which Analyst Should I Follow If I Want to Buy IN:GLAND and Sell After:

1 Month

xxx

Success Rate

1/1 ratings generated profit

Average Return

+6.50%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +6.50% per trade.

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+6.50%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +6.50% per trade.

1 Year

Alankar GarudeKotak Mahindra

Success Rate

1/1 ratings generated profit

Average Return

+6.50%

reiterated a sell rating 26 days ago

Copying Alankar Garude's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +6.50% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+6.50%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +6.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GLAND Analyst Recommendation Trends

Rating

Dec 24

Jan 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GLAND has received 0 Buy Ratings, 1 Hold Ratings, and 3 Sell Ratings. GLAND average Analyst price target in the past 3 months is ₹1,642.50.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

GLAND Financial Forecast

GLAND Earnings Forecast

Next quarter’s earnings estimate for GLAND is ₹12.46 with a range of ₹11.00 to ₹13.26. The previous quarter’s EPS was ₹9.90. GLAND beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 55.77% of the time in the same period. In the last calendar year GLAND has Preformed in-line its overall industry.

GLAND Sales Forecast

Next quarter’s sales forecast for GLAND is ₹15.35B with a range of ₹14.05B to ₹16.75B. The previous quarter’s sales results were ₹14.06B. GLAND beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.15% of the time in the same period. In the last calendar year GLAND has Outperformed its overall industry.

GLAND Stock Forecast FAQ

What is IN:GLAND’s average 12-month price target, according to analysts?

Based on analyst ratings, Gland Pharma Ltd.’s 12-month average price target is ₹1,642.50.

What is IN:GLAND’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for IN:GLAND, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Gland Pharma Ltd. a Buy, Sell or Hold?

Gland Pharma Ltd. has a consensus rating of Moderate Sell, which is based on 0 buy ratings, 1 hold ratings and 3 sell ratings.

What is Gland Pharma Ltd.’s share price target?

The average share price target for Gland Pharma Ltd. is ₹1,642.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹1,790.00 ,and the lowest forecast is ₹1,525.00. The average share price target represents -2.17% Decrease from the current price of ₹1,678.95.

What do analysts say about Gland Pharma Ltd.?

Gland Pharma Ltd.’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Gland Pharma Ltd.?

To buy shares of IN:GLAND, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Gland Pharma Ltd. (GLAND) Stock Forecast & Price Target

GLAND Analyst Ratings

GLAND Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gland Pharma Ltd.

GLAND Analyst Recommendation Trends

GLAND Financial Forecast

GLAND Earnings Forecast

GLAND Sales Forecast

GLAND Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts